Ruxolitinib improves outcomes in association with altered fibroblast immunobiology in mouse models of Sjögren’s disease

Clicks: 1
ID: 339467
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #64 of 64 articles by views in international journal of rheumatology

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
OBJECTIVE: Sjögren Disease (SjD) is a common rheumatologic disease with symptoms of dryness attributed to autoimmune exocrinopathy. JAK-STAT signaling pathway activity contributes to SjD salivary gland pathogenesis. We hypothesized that treatment of SjD model mice with ruxolitinib, a JAK-inhibitor, would improve disease course. METHODS: NOD.B10 and Aec SjD model mice were treated with vehicle or ruxolitinib for two weeks. We measured plasma immunoglobulins and cytokines, and assessed submandibular salivary glands (SMSGs) histologically, with flow cytometry, and spatial transcriptomics. RESULTS: Aec mice had a more robust inflammatory profile than NOD.B10 mice as measured by SMSG lymphocytic infiltrate, peripheral immunoglobulins and cytokine concentrations. Ruxolitinib treatment reduced plasma [IgG], [CXCL13], and focus score in Aec but not NOD.B10 mice. In Aec mice, flow cytometry showed reductions in phosphorylated (p) STAT1 in SMSG epithelial cells, leukocytes, and fibroblasts with treatment. pSTAT1 correlated with salivary flow rate and focus score. Spatial transcriptomic sequencing and immunofluorescence of SMSGs revealed a treatment effect upon fibroblast-macrophage spatial relationships. CONCLUSION: Ruxolitinib treatment improved disease course in Aec mice but not NOD.B10 mice, suggesting these mice model different SjD subpopulations and ruxolitinib efficacy may be subpopulation dependent. Flow cytometry, spatial transcriptomics, and immunostaining results implicated ruxolitinib-induced changes of fibroblast-immune cell interactions in the SMSG thereby suggesting these unique interactions as a pathogenic element and novel treatment target. These results underscore the therapeutic potential of JAK-STAT pathway inhibition for treatment of SjD, and with ruxolitinib specifically, at least for specific SjD subpopulations.
Reference Key
openalex_W7225725368 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ryan J. Adam, Ilya Gurevic, Eiko Yamada, Addie Vande Loo, Franklin P Zhou, Sara S. McCoy
Are you one of these authors? Claim your profile
Journal international journal of rheumatology
Year 2026
DOI
10.1093/rheumatology/keag619
URL
https://doi.org/10.1093/rheumatology/keag619
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.